Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

REMEVi vs Somi Health

REMEVi
Graded #70

Higher grade

vs+4.799999999999997
Somi Health
Graded #141

Lower grade

The verdict

REMEVi takes it — 73.5/100 to 68.7/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSomi Health +9
57
66
Dose & formulationREMEVi +8
83
75
Clinical oversightREMEVi +4
86
82
Labs & monitoringREMEVi +2
55
53
FulfillmentREMEVi +21
97
76
Contract termsREMEVi +22
69
47
REMEVi · left barSomi Health · right bar

The numbers

MetricREMEViSomi Health
WeighScore73.5/10068.7/100
GradeCC
Scorecard rank#70#141
Semaglutide$219/mo$135/mo (starting dose, compounded)
Tirzepatide$319/mo$165/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Somi Health

Graded #141 · C

Strengths

  • Among the lowest compounded prices: semaglutide $135/mo, tirzepatide $165/mo (3-month plan)
  • Oral semaglutide tablet option for those who want no injections
  • One price at any dose, with the medical visit and shipping included
  • LegitScript Approved seal displayed; partnered with 503A pharmacies
  • Free 2-5 day shipping; no insurance required

Where it loses points

  • Compounded only - no brand-name Wegovy, Zepbound, Ozempic or Mounjaro
  • Homepage advertises a 100% money-back guarantee but Terms state all sales are final, no refunds on medication
  • Partner pharmacies are not individually named (material transparency gap)
  • No single prescribing medical group named; only affiliated professional entities
  • State availability not published; confirmed only during intake

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard